TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20231568

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 7818

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 7818
Study: 18602144

Group type: EXPERIMENTAL
Intervention: Experimental group (low-fat, plant-based diet, exercise, stress management, group support)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Untreated experimental patients
Number of subjects: 93

Group type: COMPARATOR
Intervention: Untreated control patients
Number of subjects: 93
Study: 17067119

Group type: EXPERIMENTAL
Intervention: Pemetrexed with cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 12730476

Group type: EXPERIMENTAL
Intervention: Balanced protein energy supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High protein supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Micronutrient supplements
Number of subjects: 0
Study: 11039737

Group type: EXPERIMENTAL
Intervention: Nerve Fiber Analyzer measurements (single image) in healthy volunteers
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Nerve Fiber Analyzer measurements (single image) in patients with glaucoma
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Nerve Fiber Analyzer measurements (mean-of-three image)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Nerve Fiber Analyzer measurements across three different instruments
Number of subjects: 55
Study: 8659419

Group type: EXPERIMENTAL
Intervention: Helical CT (HC) acquisition after contrast injection at 6 ml/sec
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dynamic sequential CT (DS) acquisition after contrast injection at 2 ml/sec
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Helical CT (HC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dynamic sequential CT (DS)
Number of subjects: 100
Study: 1573555

Group type: EXPERIMENTAL
Intervention: Neomycin complexed on xanthan, administered in a unique daily dose
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ampicillin or furazolidone, administered for 5-10 days or longer
Number of subjects: 100
Study: 3887877

Group type: EXPERIMENTAL
Intervention: Sotalol (160 mg once daily, increased to 320 mg, 480 mg, and 640 mg if necessary)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Procainamide (1 gm three times/day, increased to 1.5 gm three times/day if plasma concentrations were insufficient)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both sotalol and procainamide
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 33

Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 33
Study: 30917287

Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry consumption (MC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise prior to HF meal with Montmorency tart cherry consumption (E+MC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Exercise prior to HF meal with placebo (E+P)
Number of subjects: 12
Study: 28791808

Group type: EXPERIMENTAL
Intervention: Sonography guided injection of hyaluronic acid
Number of subjects: 61

Group type: COMPARATOR
Intervention: Blind injection of hyaluronic acid
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups (Sonography guided and Blind injection)
Number of subjects: 61
Study: 27566502

Group type: EXPERIMENTAL
Intervention: Education on use of sleep-enhancing tools (eye mask, ear plugs, white noise machine)
Number of subjects: 120

Group type: COMPARATOR
Intervention: General benefits of sleep discussion (control)
Number of subjects: 120
Study: 24182765

Group type: EXPERIMENTAL
Intervention: Impact(®) perioperatively (group C)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Reference diet (group A, control)
Number of subjects: 312
Study: 23569894

Group type: EXPERIMENTAL
Intervention: Aqueous extract of Vernonia amygdalina
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunace(®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both Vernonia amygdalina extract and Immunace(®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 20685190

Group type: EXPERIMENTAL
Intervention: In-office training for pediatric primary care clinicians
Number of subjects: 397

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Children with possible or probable SDQ scores
Number of subjects: 397
Study: 18242357

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg once daily for 5 days
Number of subjects: 1109

Group type: COMPARATOR
Intervention: Ciprofloxacin 400 mg intravenously and/or 500 mg orally twice daily for 10 days
Number of subjects: 1109
Study: 15848357

Group type: EXPERIMENTAL
Intervention: Open repair
Number of subjects: 1622

Group type: COMPARATOR
Intervention: Laparoscopic repair
Number of subjects: 1622

Group type: EXPERIMENTAL
Intervention: Open and laparoscopic repair
Number of subjects: 1622
Study: 12629102

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10482826

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily
Number of subjects: 197

Group type: COMPARATOR
Intervention: Salmeterol 50 microg twice daily
Number of subjects: 197
Study: 7851594

Group type: EXPERIMENTAL
Intervention: CA-125 in seminal plasma
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CA-19.9 in seminal plasma
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CA-195 in seminal plasma
Number of subjects: 46
Study: 2117186

Group type: EXPERIMENTAL
Intervention: OM‐85 BV
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 7006476

Group type: EXPERIMENTAL
Intervention: Daily administration of isoniazid, rifampin, and ethambutol for 8 weeks, followed by daily for 18 weeks
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Twice weekly administration of isoniazid, rifampin, and ethambutol during the continuation phase
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Once weekly administration of isoniazid, rifampin, and ethambutol during the continuation phase
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Twice weekly administration of isoniazid and rifampin during the continuation phase
Number of subjects: 411
Study: 31853709

Group type: EXPERIMENTAL
Intervention: Inotersen (Tegsedi™)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31337958

Group type: EXPERIMENTAL
Intervention: NXT15906F6-250 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: NXT15906F6-400 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 27718143

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg per day (12h sampling)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg per day (24h sampling)
Number of subjects: 16
Study: 25982703

Group type: EXPERIMENTAL
Intervention: Nurse telephone triage consultation
Number of subjects: 9154

Group type: COMPARATOR
Intervention: GP face-to-face consultation
Number of subjects: 9154

Group type: COMPARATOR
Intervention: GP telephone triage consultation with no subsequent same day care
Number of subjects: 9154

Group type: COMPARATOR
Intervention: GP telephone triage consultation with subsequent face-to-face consultation
Number of subjects: 9154

Group type: COMPARATOR
Intervention: Nurse telephone triage consultation with subsequent face-to-face consultation
Number of subjects: 9154
Study: 22849311

Group type: EXPERIMENTAL
Intervention: Green leafy porridges (including coconut milk and various leaf extracts)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose control
Number of subjects: 0
Study: 20805142

Group type: EXPERIMENTAL
Intervention: Light-cured resin-modified glass ionomer cement (RMGIC) with 15% phosphoric acid etching and without water contamination
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Light-cured resin-modified glass ionomer cement (RMGIC) with 15% phosphoric acid etching and with water contamination
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Light-cured resin-modified glass ionomer cement (RMGIC) without acid etching and without water contamination
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Light-cured resin-modified glass ionomer cement (RMGIC) without acid etching and with water contamination
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional light-cured Transbond composite resin under acid etching and without water contamination
Number of subjects: 100
Study: 19632710

Group type: EXPERIMENTAL
Intervention: Placebo with enhanced messages
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Montelukast with enhanced messages
Number of subjects: 601

Group type: COMPARATOR
Intervention: Neutral placebo
Number of subjects: 601

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Montelukast with neutral messages
Number of subjects: 601

Group type: COMPARATOR
Intervention: Placebo with neutral messages
Number of subjects: 601
Study: 17078894

Group type: EXPERIMENTAL
Intervention: Electronic interactive referral pro forma
Number of subjects: 265707

Group type: EXPERIMENTAL
Intervention: Educational outreach visit by a local colorectal surgeon
Number of subjects: 265707

Group type: COMPARATOR
Intervention: Combined software arms (electronic pro forma and educational outreach)
Number of subjects: 265707

Group type: COMPARATOR
Intervention: Combined educational outreach arms
Number of subjects: 265707

Group type: EXPERIMENTAL
Intervention: Pro forma practices
Number of subjects: 265707
Study: 15284371

Group type: EXPERIMENTAL
Intervention: Lutein-enriched egg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lutein supplement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lutein ester supplement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Spinach
Number of subjects: 10
Study: 10965395

Group type: EXPERIMENTAL
Intervention: Promethazine oral syrup (50 mg, 10 mL)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Promethazine rectal suppository (50 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Promethazine rectal suppository (two 12.5 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Promethazine rectal suppository (25 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All formulations (oral syrup and rectal suppositories)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Three suppository treatments
Number of subjects: 36
Study: 9043723

Group type: EXPERIMENTAL
Intervention: Surgeons' estimates of cardiac output (CO)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Anaesthetists' estimates of cardiac output (CO)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Surgeons' estimates of systemic vascular resistance (SVR)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Anaesthetists' estimates of systemic vascular resistance (SVR)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Management based on subjective values
Number of subjects: 35
Study: 7701651

Group type: EXPERIMENTAL
Intervention: Prompt endoscopy (group 1)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Empirical treatment strategy (group 2)
Number of subjects: 414
Study: 2649339

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 5)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (n = 5)
Number of subjects: 10
Study: 367239

Group type: EXPERIMENTAL
Intervention: Idoxuridine (IDU)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vidarabine (ara‐A)
Number of subjects: 10
Study: 31820361

Group type: EXPERIMENTAL
Intervention: Acetazolamide plus indomethacin, enalapril, and spironolactone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Indomethacin, enalapril, and spironolactone (Control)
Number of subjects: 22
Study: 31182140

Group type: EXPERIMENTAL
Intervention: Hou Gu Mi Xi (HGMX)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 28562541

Group type: EXPERIMENTAL
Intervention: Ropivacaine-epinephrine
Number of subjects: 148

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Ropivacaine-epinephrine and Normal saline (Control)
Number of subjects: 148
Study: 25486391

Group type: EXPERIMENTAL
Intervention: Alcohol Skills Training Program (ASTP)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Brief Alcohol Screening and Intervention for College Students (BASICS)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Treatment-as-usual Alcohol Diversion Program (ADP)
Number of subjects: 61
Study: 24419119

Group type: EXPERIMENTAL
Intervention: RT plus PCV chemotherapy
Number of subjects: 251

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Both study arms (RT and RT plus PCV)
Number of subjects: 251
Study: 22209215

Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 250
Study: 19540386

Group type: EXPERIMENTAL
Intervention: Psychological interventions (group 1 and group 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spiritual interventions (group 2 and group 4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (group 5)
Number of subjects: 0
Study: 18246682

Group type: EXPERIMENTAL
Intervention: Acupuncture plus intensive pulse light irradiation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 96
Study: 15034745

Group type: EXPERIMENTAL
Intervention: Minimized ANN model
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Best kinetic model
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Maximized model
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Morphologic model
Number of subjects: 89

Group type: COMPARATOR
Intervention: Expert radiologist
Number of subjects: 89
Study: 11588440

Group type: EXPERIMENTAL
Intervention: Methylene blue (MB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 20
Study: 9050948

Group type: EXPERIMENTAL
Intervention: Low dose GH: 16 IU/m2/week
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: High dose GH: 28 IU/m2/week
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: GH: 24 IU/m2/week + Oxa: 0.06 mg/kg/day
Number of subjects: 67

Group type: COMPARATOR
Intervention: Untreated girls with TS
Number of subjects: 67
Study: 8466063

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg intramuscularly every 6 h after an initial dose of 60 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3532404

Group type: EXPERIMENTAL
Intervention: Pirprofen (rengasil) combined with small doses of corticosteroids
Number of subjects: 93
Study: 29923323

Group type: EXPERIMENTAL
Intervention: Sitagliptin (intervention group)
Number of subjects: 14771

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 14771
Study: 26945321

Group type: EXPERIMENTAL
Intervention: Higher density treatment
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Lower density treatment
Number of subjects: 7

Group type: COMPARATOR
Intervention: Both treatment densities
Number of subjects: 7
Study: 25231953

Group type: EXPERIMENTAL
Intervention: Everolimus (EVE) 10 mg/day plus Exemestane (EXE) 25 mg/day
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo (PBO) plus Exemestane (EXE) 25 mg/day
Number of subjects: 410
Study: 22405699

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus long-term androgen deprivation (LTAD)
Number of subjects: 250
Study: 21164551

Group type: EXPERIMENTAL
Intervention: Marine collagen peptides (MCPs) 13 g daily for 3 months
Number of subjects: 100
Study: 17645254

Group type: EXPERIMENTAL
Intervention: Body acupuncture
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Auricular and body acupuncture
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined auricular and body acupuncture treatment plus moving cupping on back‐shu points
Number of subjects: 80
Study: 16222322

Group type: COMPARATOR
Intervention: 5FU alone
Number of subjects: 1327

Group type: EXPERIMENTAL
Intervention: 5FU+LEV
Number of subjects: 1327

Group type: EXPERIMENTAL
Intervention: 5FU+FA
Number of subjects: 1327

Group type: EXPERIMENTAL
Intervention: 5FU+LEV+FA
Number of subjects: 1327
Study: 11887541

Group type: EXPERIMENTAL
Intervention: Metoclopramide group (n = 26)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo group (n = 30)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study: 10208997

Group type: EXPERIMENTAL
Intervention: abciximab with low-dose heparin (70 U/kg initial bolus)
Number of subjects: 2792

Group type: EXPERIMENTAL
Intervention: abciximab with standard-dose heparin (100 U/kg initial bolus)
Number of subjects: 2792

Group type: COMPARATOR
Intervention: placebo with standard-dose heparin (100 U/kg initial bolus)
Number of subjects: 2792

Group type: EXPERIMENTAL
Intervention: abciximab therapy
Number of subjects: 2792

Group type: EXPERIMENTAL
Intervention: periprocedural myocardial infarctions suppressed by abciximab
Number of subjects: 2792
Study: 7790694

Group type: EXPERIMENTAL
Intervention: High Protein diet (HP) at 1.5 g/kg body weight/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Marginal Protein diet (MP) at 1.0 g/kg body weight/day
Number of subjects: 24
Study: 2183599

Group type: EXPERIMENTAL
Intervention: Three or more cups of filter-brewed coffee per day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no coffee consumption)
Number of subjects: 21
Study: 7241554

Group type: EXPERIMENTAL
Intervention: Highly structured sequence on colorectal cancer (n = 180)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Unstructured sequence on colorectal cancer (n = 180)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Colorectal cancer self-instructional sequence (n = 65)
Number of subjects: 245
Study: 31142441

Group type: EXPERIMENTAL
Intervention: Empagliflozin (EMPA) 10 mg
Number of subjects: 7020

Group type: EXPERIMENTAL
Intervention: Empagliflozin (EMPA) 25 mg
Number of subjects: 7020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study: 28196207

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg once daily (400 mg/d)
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 800 mg twice daily (800 mg/d)
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Imatinib as sole therapy
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Additional systemic agents
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Resequencing studies
Number of subjects: 695
Study: 26281285

Group type: EXPERIMENTAL
Intervention: Financial incentives of Euro 150
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Financial incentives of Euro 300
Number of subjects: 700

Group type: COMPARATOR
Intervention: No financial incentive
Number of subjects: 700
Study: 23340492

Group type: EXPERIMENTAL
Intervention: Dietary intervention (daily supplementation with 1200 mg n-3 LCPUFAs and dietary counseling to reduce arachidonic acid (AA) intake)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 208

Group type: COMPARATOR
Intervention: Habitual diet (Control)
Number of subjects: 208
Study: 20666677

Group type: EXPERIMENTAL
Intervention: Succinylated atelocollagen
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ablative fractional resurfacing laser
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 19388569

Group type: EXPERIMENTAL
Intervention: Early and prolonged peritoneal lavage
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 35
Study: 17971621

Group type: EXPERIMENTAL
Intervention: Direct attention training for reading impairment in mild aphasia
Number of subjects: 1
Study: 15245938

Group type: EXPERIMENTAL
Intervention: Concurrent gemcitabine (initial dose 10 mg/m2, increased as tolerated) and radiotherapy (RT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Higher doses of gemcitabine (greater than 20 mg/m2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Patients who experienced dose-limiting toxicity (DLT)
Number of subjects: 24
Study: 11403535

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs) for long-term management of H. pylori-negative ulcers
Number of subjects: 0

Group type: COMPARATOR
Intervention: H2-receptor antagonists
Number of subjects: 0
Study: 9678430

Group type: EXPERIMENTAL
Intervention: Intravenous iron gluconate
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oral ferrous iron
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no iron supplementation)
Number of subjects: 39
Study: 8048390

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) plus Radiotherapy (RT)
Number of subjects: 64
Study: 2659312

Group type: EXPERIMENTAL
Intervention: High energy food supplement of 3.31 MJ for the first 3 months of the 6-month intervention period.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard health care similar to that offered by the local health service (unsupplemented group).
Number of subjects: 0
Study: 31809657

Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NTG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 32
Study: 31444897

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 222
Study: 27900778

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) and stabilization
Number of subjects: 72
Study: 25423953

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent (BES)
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent (BES) in STEMI patients
Number of subjects: 573
Study: 23260801

Group type: EXPERIMENTAL
Intervention: Banded LRYGB
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unbanded LRYGB
Number of subjects: 60